Zoran Culig1, Frédéric R Santer. 1. Experimental Urology, Department of Urology, Innsbruck Medical University, Anichstrasse 35, 6020, Innsbruck, Austria. zoran.culig@i-med.ac.at
Abstract
OBJECTIVES: Androgen receptor (AR) action in benign and malignant tissue is potentiated by a number of co-regulatory proteins that may interact with one or more receptor domains. With improvement of research methodologies, it became possible to detect a number of co-activators whose expression is increased in prostate cancer tissue. METHODS: Manuscripts describing prostate cancer-relevant regulation of cellular events by co-activators are selected and summarized. RESULTS: AR co-activators may regulate histone modification, proteasomal degradation, chaperones, sumoylation, chromatin remodeling, and cytoskeleton. Some of them (TIF-2) are up-regulated by androgens, whereas the expression of others increases during androgen ablation (p300, CBP, and Tip60). Most co-factors are important for the stimulation of cellular proliferation, although in some cases (ART-27), they act as tumor suppressors and are deleted in prostate cancer tissue. In addition to stimulating AR, some co-activators suppress apoptosis in prostate cancer cells that do not express the AR (p300 and SRC-3). It was recently shown that the inhibition of p300 slows down proliferation, stimulates apoptosis, and inhibits migration and invasion. CONCLUSIONS: Co-factors whose down-regulation results in the alterations of multiple cellular functions may be valid targets for novel therapies in advanced prostate cancer.
OBJECTIVES:Androgen receptor (AR) action in benign and malignant tissue is potentiated by a number of co-regulatory proteins that may interact with one or more receptor domains. With improvement of research methodologies, it became possible to detect a number of co-activators whose expression is increased in prostate cancer tissue. METHODS: Manuscripts describing prostate cancer-relevant regulation of cellular events by co-activators are selected and summarized. RESULTS:AR co-activators may regulate histone modification, proteasomal degradation, chaperones, sumoylation, chromatin remodeling, and cytoskeleton. Some of them (TIF-2) are up-regulated by androgens, whereas the expression of others increases during androgen ablation (p300, CBP, and Tip60). Most co-factors are important for the stimulation of cellular proliferation, although in some cases (ART-27), they act as tumor suppressors and are deleted in prostate cancer tissue. In addition to stimulating AR, some co-activators suppress apoptosis in prostate cancer cells that do not express the AR (p300 and SRC-3). It was recently shown that the inhibition of p300 slows down proliferation, stimulates apoptosis, and inhibits migration and invasion. CONCLUSIONS: Co-factors whose down-regulation results in the alterations of multiple cellular functions may be valid targets for novel therapies in advanced prostate cancer.
Authors: Irina U Agoulnik; Ajula Vaid; William E Bingman; Halime Erdeme; Anna Frolov; Carolyn L Smith; Gustavo Ayala; Michael M Ittmann; Nancy L Weigel Journal: Cancer Res Date: 2005-09-01 Impact factor: 12.701
Authors: Dennis J van de Wijngaart; Hendrikus J Dubbink; Michel Molier; Carola de Vos; Guido Jenster; Jan Trapman Journal: Prostate Date: 2011-02-15 Impact factor: 4.104
Authors: Siting Feng; Qizhu Tang; Meng Sun; Jae Yeon Chun; Christopher P Evans; Allen C Gao Journal: Mol Cancer Ther Date: 2009-02-24 Impact factor: 6.261
Authors: Ashley T Fancher; Yun Hua; Daniel P Camarco; David A Close; Christopher J Strock; Paul A Johnston Journal: Assay Drug Dev Technol Date: 2016-09-08 Impact factor: 1.738
Authors: Marie C Hupe; M Raschid Hoda; Friedemann Zengerling; Sven Perner; Axel S Merseburger; Marcus V Cronauer Journal: World J Urol Date: 2018-06-22 Impact factor: 4.226
Authors: Ashley T Fancher; Yun Hua; Daniel P Camarco; David A Close; Christopher J Strock; Paul A Johnston Journal: Assay Drug Dev Technol Date: 2018-08-15 Impact factor: 1.738